Skip navigation
Browsing by Author Houghton, B.
Showing results 1 to 4 of 4
| Preview | Issue Date | Title / Name | Author(s) |
| Aug-2016 | The effect of pulmonary function testing on bleomycin dosing in germ cell tumours | Roncolato, F. T.; Chatfield, M.; Houghton, B.; Toner, G.; Stockler, M.; Thomson, D.; Friedlander, M.; Gurney, H.; Rosenthal, M.; Grimison, P.; Houghton, Baerin | |
| May-2024 | Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799. | Reck, M.; Lee, K. H.; Frost, N.; Breder, V. V.; Kowalski, D. M.; Levchenko, E.; Reguart, N.; Martinez-Marti, A.; Houghton, B.; Paoli, J. B.; Safina, S.; Liu, H.; Novinskiy, V.; Dettman, E. J.; Kobie, J.; Jabbour, S. K.; Houghton, Baerin | |
| Nov-2024 | Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study | Cohen, B.; Rapoport, B.; Chan, S. w.; Ruff, P.; Arance, A.; Eizmendi, K. M.; Houghton, B.; Brown, M. P.; Zielinski, R. M.; Couselo, E. M.; Lyle, M.; Anderson, J. R.; Jain, L.; de Alwis, D.; Lala, M.; Akala, O.; Chartash, E.; Jacobs, C.; Houghton, Baerin | |
| Nov-2020 | Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials | Borghaei, H.; Langer, C. L.; Paz-Ares, L.; Rodriguez-Abreu, D.; Halmos, B.; Garassino, M. C.; Houghton, B.; Kurata, T.; Cheng, Y.; Lin, J.; Pietanza, M. C.; Piperdi, B.; Gadgeel, S. M.; Houghton, Baerin | |
